Re: Cristina Masini, Cinzia Iotti, Ugo De Giorgi, et al. Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study. Eur Urol. 2022;81:274-82

Affiliations

¹ Radiation Oncology Unit, Azienda Ospedaliero Universitaria Careggi, Florence, Italy. Electronic address: francolinigiulio@gmail.com.
² Department of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy.
³ Radiation Oncology Unit, Azienda Ospedaliero Universitaria Careggi, Florence, Italy; Department of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy.

Comment

Giulio Francolini et al. Eur Urol. 2022 Apr.

. 2022 Apr;81(4):e98-e99.

doi: 10.1016/j.eururo.2021.11.034. Epub 2022 Jan 4.

¹ Radiation Oncology Unit, Azienda Ospedaliero Universitaria Careggi, Florence, Italy. Electronic address: francolinigiulio@gmail.com.
² Department of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy.
³ Radiation Oncology Unit, Azienda Ospedaliero Universitaria Careggi, Florence, Italy; Department of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy.

No abstract available

Comment on

Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study.
Masini C, Iotti C, De Giorgi U, Bellia RS, Buti S, Salaroli F, Zampiva I, Mazzarotto R, Mucciarini C, Vitale MG, Bruni A, Lohr F, Procopio G, Caffo O, Nole F, Morelli F, Baier S, Buttigliero C, Ciammella P, Timon G, Fantinel E, Carlinfante G, Berselli A, Pinto C. Masini C, et al. Eur Urol. 2022 Mar;81(3):274-282. doi: 10.1016/j.eururo.2021.09.016. Epub 2021 Oct 1. Eur Urol. 2022. PMID: 34602312 Clinical Trial.